Analysts Offer Predictions for Organogenesis FY2025 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Organogenesis in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of ($0.08) per share for the year. The consensus estimate for Organogenesis' current full-year earnings is ($0.07) per share.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.11. The company had revenue of $115.18 million for the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the prior year, the business posted $0.02 EPS.

Organogenesis Stock Up 0.9 %

Shares of NASDAQ:ORGO traded up $0.03 during trading on Thursday, hitting $3.53. 314,855 shares of the company were exchanged, compared to its average volume of 557,682. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average price of $3.48 and a two-hundred day moving average price of $3.11. The stock has a market cap of $443.83 million, a price-to-earnings ratio of -58.83 and a beta of 1.77. Organogenesis has a fifty-two week low of $2.16 and a fifty-two week high of $4.57.

Insiders Place Their Bets

In other news, CEO Gary S. Gillheeney sold 41,052 shares of the business's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $3.52, for a total value of $144,503.04. Following the transaction, the chief executive officer now directly owns 3,359,726 shares of the company's stock, valued at $11,826,235.52. The trade was a 1.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 278,116 shares of company stock worth $991,190 in the last 90 days. Company insiders own 36.90% of the company's stock.

Institutional Trading of Organogenesis

Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its stake in Organogenesis by 19.6% in the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company's stock valued at $5,702,000 after acquiring an additional 333,123 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Organogenesis by 1,350.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company's stock valued at $265,000 after purchasing an additional 88,175 shares during the period. Squarepoint Ops LLC boosted its position in shares of Organogenesis by 80.9% during the 2nd quarter. Squarepoint Ops LLC now owns 91,034 shares of the company's stock valued at $255,000 after acquiring an additional 40,710 shares during the last quarter. AQR Capital Management LLC grew its stake in Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company's stock worth $6,353,000 after buying an additional 986,132 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Organogenesis by 15.4% in the second quarter. The Manufacturers Life Insurance Company now owns 30,984 shares of the company's stock valued at $87,000 after acquiring an additional 4,130 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.